

Helsinn to provide an independent educational grant support for a satellite symposium on Comprehensive Cancer Care for Common GI Abnormalities in Cancer Patients at 2014 MASCC/ISOO International Symposium

**Lugano, Switzerland, June 27, 2014** – Helsinn Group, the company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Comprehensive Cancer Care for Common Gastrointestinal (GI) Abnormalities in Cancer Patients, at the 2014 MASCC/ISOO International Symposium, in Miami, Florida, on Friday, June 27, 2014.

Helsinn has awarded a grant to Educational Concepts Group, LLC (ECG), a provider of continuing medical education in hematology and oncology. ECG has developed an education program for MASCC/ISOO 2014, designed to improve awareness of the latest advances in the understanding of the pathogenesis and clinical aspects of common GI abnormalities associated with cancer, including anorexia-cachexia associated with cancer and chemotherapy-induced nausea and vomiting. The program aims to educate healthcare providers on the most recent developments in therapy and update them on the latest clinical management strategies.

Helsinn's Chief Executive Officer, Mr. Riccardo Braglia, commented: "Helsinn is pleased to be able to support this initiative, which is tailored to educate healthcare providers in advances in tackling the most challenging side-effects of cancer and cancer treatment. This confirms our commitment to building better todays for people with cancer. With quality, respect and integrity at the heart of everything we do, we aim to improve the quality of life for every person with cancer -- today, now, when it counts."

The satellite symposium will take place in conjunction with the 2014 MASCC/ISOO International Symposium at the Miami Beach Convention Center, USA, on Friday, June 27, 2014 from 12:00pm to 1:30pm, Level 1, Room A101/102. It will involve a live case-based format, a panel discussion, and an audience Q&A session. The symposium will be chaired by Egidio Del Fabbro, MD, director of palliative care at Virginia Commonwealth University, Richmond, Virginia, USA.



## **About the Helsinn Group**

Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the U.S. and a Representative Office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care. Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at www.helsinn.com

## For more information, please contact:

## **Helsinn Group**

Paola Bonvicini Head of Communication & Press Office

Tel: +41 91-985-21-21 info-hhc@helsinn.com

## For media/external inquiries

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Melissa Jumbo

Tel: +44 (0)203 709 5700

Helsinn@consilium-comms.com